title: Effect of Li+ therapy and site of origin on cerebrospinal fluid beta-amyloid precursor protein derivatives.
authors.affiliation: Institute of Neurology, Queen Square, London.
authors.forename: N A
authors.initials: NA
authors.lastname: Clarke
authors.forename: A W
authors.initials: AW
authors.lastname: Procter
authors.forename: M T
authors.initials: MT
authors.lastname: Webster
authors.forename: P T
authors.initials: PT
authors.lastname: Francis
authors.forename: A D
authors.initials: AD
authors.lastname: Hodgkiss
authors.forename: D M
authors.initials: DM
authors.lastname: Bowen
mesh_terms: D000544:Alzheimer Disease / Q000134:cerebrospinal fluid; D016564:Amyloid beta-Protein Precursor / Q000134:cerebrospinal fluid*; D000928:Antidepressive Agents / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000627:therapeutic use; D001284:Atrophy; D001714:Bipolar Disorder / Q000134:cerebrospinal fluid / Q000188:drug therapy; D001921:Brain / Q000473:pathology; D003866:Depressive Disorder / Q000134:cerebrospinal fluid* / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D008094:Lithium / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged
chemical_list: D016564:Amyloid beta-Protein Precursor; D000928:Antidepressive Agents; D014150:Antipsychotic Agents; D008094:Lithium